MedTrace Logo

Gait Training for Persons With Stroke

NCT00612300 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2010-02-17

No results posted yet for this study

Summary

The objective of this study is to investigate the effects of an automatic gait trainer (Lokomat) handled by physical therapists compared with categorized gait training by physical therapists in ambulatory stroke patients. Gait speed, gait distance and gait symmetry are used to evaluate study effects.

Hypotheses: 1) The Lokomat improves stroke patients gait speed, distance and symmetry more than categorized gait training.

Conditions

  • Stroke
  • Middle Cerebral Artery Infarction

Interventions

BEHAVIORAL

Lokomat - Physical therapy

A: Lokomat training, 30 minutes per day for 3 weeks, 5 days per week. B: Categorized gait training by physical therapist, 30 minutes per day for 3 weeks, 5 days per week

BEHAVIORAL

Physical therapy - Lokomat

B: Daily 30 minutes of gait training with a physical therapist, 5 days per week for 3 weeks. A: Daily 30 minutes of Lokomat training, 5 days per week for 3 weeks.

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Jørgen F Nielsen, Professor · Hammel Neurorehabilitation and Research Center, Denmark

  • Carsten Kock-Jensen, MD · Hammel Neurorehabilitation and Research Center, Denmark

  • John Brincks, PhD student · Hammel Neurorehabilitation and Reseach Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00612300 on ClinicalTrials.gov